908 DEVICES INC (MASS)
Sector: Information Technology
2026 Annual Meeting Analysis
908 DEVICES INC · Meeting: June 11, 2026
Directors FOR
3
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Class III Directors
Crandell has served since 2012 with strong venture capital and life sciences investment experience; MASS's 3-year return of -8.3% trails the peer group median by only 11.5 percentage points, well below the 20-point threshold required to trigger an against vote given the company's negative absolute return, and no overboarding, attendance, or independence concerns are present.
Brown joined the board in 2025 and is exempt from the TSR trigger under the 24-month new-director rule; he brings deep scientific and operational expertise as a co-founder and former Chief Technology and Product Officer of 908 Devices.
Hrusovsky has served since 2013 as Chairman with extensive CEO and life sciences executive experience; the 3-year peer underperformance of 11.5 percentage points does not meet the 20-point trigger threshold applicable to companies with negative absolute TSR, and no other policy flags are present.
All three Class III director nominees pass the TSR underperformance test — MASS's 3-year return of -8.3% trails the disclosed peer group median by only 11.5 percentage points, short of the 20-point threshold that applies when a company's absolute 3-year return is negative. Christopher Brown is additionally exempt as a director who joined within the past 24 months. No overboarding, attendance, independence, or qualifications concerns were identified for any nominee.
Say on Pay
✓ FORCEO
Kevin J. Knopp, Ph.D.
Total Comp
$1,553,502
Prior Support
N/A
This is the company's first say-on-pay vote (it ceased to be an emerging growth company as of December 31, 2025), so there is no prior-year shareholder vote to evaluate. The CEO's total reported compensation of $1,553,502 — consisting of $500,000 base salary, $393,751 in stock awards, $131,251 in stock option awards, $525,000 in performance bonus, and $3,500 in 401(k) match — is consistent with a reasonable pay structure for a CEO at a small-cap life sciences company (~$243M market cap), with approximately 68% of total pay in variable or performance-linked components (bonus, equity), exceeding the 50-60% variable pay threshold. The company has a Dodd-Frank-compliant clawback policy in place, equity grants vest over multi-year schedules tying executive outcomes to shareholder value, and the annual bonus was earned based on pre-set revenue, operating expense, and adjusted EBITDA targets, supporting a FOR determination.
Auditor Ratification
✓ FORAuditor
PricewaterhouseCoopers LLP
Tenure
13 yrs
Audit Fees
$1,361,660
Non-Audit Fees
$41,125
Non-audit fees (tax fees of $38,000 plus other fees of $3,125, totaling $41,125) represent approximately 3% of audit fees of $1,361,660, well below the 50% threshold that would raise independence concerns; PwC has served since 2013 (approximately 13 years), comfortably below the 25-year tenure trigger; and PwC is a Big 4 firm appropriate for a company of this size and complexity.
Overall Assessment
The 2026 annual meeting of 908 Devices presents a clean ballot with no material governance concerns: all three Class III director nominees pass the stock performance and qualifications screens, PricewaterhouseCoopers LLP presents no independence or tenure red flags, and the company's first-ever say-on-pay vote reflects a reasonable pay structure with strong variable pay weighting and a compliant clawback policy. No stockholder proposals appear on the ballot.
Compensation Peer Group
19 companies disclosed in 2026 proxy filing